Waltham, MA, April 28, 2020 — Trinity Life Sciences, a leader in global
life sciences solutions, announced today the availability of a new TGaS
benchmarking assessment that identifies the high-risk functions within pharma
that are least prepared for challenges generated by the COVID-19 pandemic.
Sales rep
training, forecasting, competitive intelligence, patient support services and
KOL relationship management are among the highest risk functions that need to
consider significant evolution to adjust to a current and post-pandemic world.
“The
COVID-19 crisis has all of us engaged with the U.S. healthcare system thinking
about how the future may look different than our collective past,” said Gary
McWalters, President of TGaS Advisors, a Division within Trinity. “With forward-looking
ideas in mind, TGaS has considered the most likely changes within the
pharmaceutical commercial model and assessed which commercial operations
functional areas are most likely to be least prepared from a
capabilities perspective for the challenges that lie ahead.”
The
dashboard can be downloaded: Impact of COVID-19 on Commercial Capabilities
by Functional Area.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner,
providing evidence-based solutions for the life sciences. With over 20 years of
experience, Trinity is committed to solving clients’ most challenging problems
through exceptional levels of service, powerful tools, and data-driven
insights. Trinity’s range of products and solutions includes industry-leading
benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity
is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
For
more information:
Elizabeth
Marshall
Trinity
Life Sciences
781-577-6376